echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Eli Lilly’s new breast cancer drug has begun to be supplied in China, and charity assistance projects have started simultaneously

    Eli Lilly’s new breast cancer drug has begun to be supplied in China, and charity assistance projects have started simultaneously

    • Last Update: 2021-05-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com





    On April 20th, Eli Lilly and Company announced that its CDK 4/6 inhibitor Weize (Abexili Tablets) will be available nationwide from April 19, 2021, and will continue to be available in many countries.


    China issued its first prescription, bringing new treatment options to Chinese patients with advanced breast cancer.
    At the same time, in order to help patients with advanced breast cancer reduce the economic burden of medication, the "Ru Ai You Li" charity assistance project initiated by the China Women's Development Foundation and supported by Eli Lilly was officially launched in Beijing, aiming to allow more patients to receive timely treatment.


    Breast cancer is the most common cancer among women worldwide.


    It is estimated that 90% of breast cancers are diagnosed at an early stage.


    Abbasilide is an oral CDK 4/6 inhibitor developed by Eli Lilly.


    In December 2020, Abexicil was approved by the National Medical Products Administration (NMPA) of China for HR-positive and HER2-negative locally advanced or metastatic breast cancer, including: 1) Used in combination with aromatase inhibitors Initial endocrine therapy for postmenopausal female patients; 2) Combined with fulvestrant for patients who have experienced disease progression after receiving endocrine therapy.


    According to the research data of MONARCH plus released by Eli Lilly in September 2019, Abexicil has achieved good effects in breast cancer patients in China.


    The approval of Abexicil in China has brought new treatment options for breast cancer patients.




    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.